Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.010 Biomarker disease BEFREE To analyze whether MAP17 could also alter this process, we used the proteasome inhibitor bortezomib (Velcade, PS-341), which is approved for the treatment of multiple myeloma and mantle cell lymphoma, although it has a high rate of resistance emergence and poor efficacy in solid tumors. 25837675 2015